Real Clinical Practice of Using Afatinib Therapy in NSCLC Patients with an Acquired EGFR T790M Mutation

被引：7

作者：

Miyazaki, Kunihiko ^{[1
]}

Tamura, Tomohiro ^{[2
]}

Kaburagi, Takayuki ^{[2
]}

Saito, Kazuhito ^{[3
,4
]}

Inagaki, Masaharu ^{[3
,4
]}

Yamashita, Takaaki ^{[5
]}

Ichimura, Hideo ^{[6
,7
]}

Nawa, Takeshi ^{[6
,7
]}

Endo, Takeo ^{[8
]}

Hayashihara, Kenji ^{[9
]}

Kimura, Masaki ^{[10
]}

Kurishima, Koichi ^{[11
]}

Nakamura, Hiroyuki ^{[12
,13
]}

Furukawa, Kinya ^{[12
,13
]}

Kikuchi, Norihiro ^{[14
]}

Satoh, Hiroaki ^{[15
]}

Hizawa, Nobuyuki ^{[16
]}

机构：

[1] Ryugasaki Saiseikai Hosp, Div Resp Med, Ryugasaki, Japan

[2] Ibaraki Cent Hosp, Resp Ctr, Kasama, Ibaraki, Japan

[3] Tsuchiura Kyodo Gen Hosp, Div Resp Med, Tsuchiura, Ibaraki, Japan

[4] Tsuchiura Kyodo Gen Hosp, Div Thorac Surg, Tsuchiura, Ibaraki, Japan

[5] JA Toride Med Ctr, Div Resp Med, Toride, Japan

[6] Hitachi Gen Hosp, Div Resp Med, Hitachi, Ibaraki, Japan

[7] Hitachi Gen Hosp, Div Thorac Surg, Hitachi, Ibaraki, Japan

[8] Mito Med Ctr, Div Resp Med, Mito, Ibaraki, Japan

[9] Ibarakihigashi Hosp, Div Resp Med, Tokai, Ibaraki, Japan

[10] Tsukuba Mem Hosp, Div Thorac Surg, Tsukuba, Ibaraki, Japan

[11] Tsukuba Med Ctr Hosp, Div Resp Med, Tsukuba, Ibaraki, Japan

[12] Tokyo Med Univ, Div Resp Med, Ibaraki Med Ctr, Ami Machi, Tokyo, Japan

[13] Tokyo Med Univ, Div Thorac Surg, Ibaraki Med Ctr, Ami Machi, Tokyo, Japan

[14] Kasumigaura Med Ctr, Div Resp Med, Tsuchiura, Ibaraki, Japan

[15] Univ Tsukuba, Mito Med Ctr, Mito Kyodo Gen Hosp, Div Resp Med, Mito, Ibaraki, Japan

[16] Univ Tsukuba, Fac Clin Med, Tsukuba, Ibaraki, Japan

来源：

ANTICANCER RESEARCH | 2018年 / 38卷 / 09期

关键词：

Clinical practice; afatinib; non-small cell lung cancer; acquired T790M mutation; osimertinib; immune-checkpoint inhibitor; CELL LUNG-CANCER; 1ST-LINE TREATMENT; OPEN-LABEL; GEFITINIB; ADENOCARCINOMA; OSIMERTINIB; EXPERIENCE; ERLOTINIB; RECEPTOR;

D O I：

10.21873/anticanres.12871

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background/Aim: To describe real clinical outcomes when using afatinib therapy to treat non-small cell lung cancer patients who have an acquired EGFR T790M mutation. Materials and Methods: A retrospective chart review was conducted from January 2013 to November 2017 sourced from 15 medical institutes that cover a population of three million people. Results: There were 74 patients who met the above-mentioned criteria. Treatment outcomes with afatinib, in patients with or without tyrosine kinase inhibitor (TKI) therapy prior to afatinib, were similar to previously reported clinical trials. Stratification of patients by the presence or absence of TKI pretreatment before afatinib, and the presence or absence of an acquired T790M mutation found no statistical difference in overall survival. Conclusion: This population-based study found that the disadvantages of pretreatment before afatinib, and absence of an acquired T790M EGFR mutation, could be overcome by an appropriate treatment strategy in clinical practice.

引用

页码：5409 / 5415

页数：7

共 50 条

[41] Afatinib increases sensitivity to radiation in non-small cell lung cancer cells with acquired EGFR T790M mutation
Zhang, Shirong
Zheng, Xiaoliang
Huang, Haixiu
Wu, Kan
Wang, Bing
Chen, Xufeng
Ma, Shenglin
ONCOTARGET, 2015, 6 (08) : 5832 - 5845
[42] The EGFR T790M Mutation in Acquired Resistance to an Irreversible Second-Generation EGFR Inhibitor
Kim, Youngwook
Ko, Jeonghun
Cui, ZhengYun
Abolhoda, Amir
Ahn, Jin Seok
Ou, Sai-Hong
Ahn, Myung-Ju
Park, Keunchil
MOLECULAR CANCER THERAPEUTICS, 2012, 11 (03) : 784 - 791
[43] The EGFR T790M Mutation in Acquired Resistance to an Irreversible Second-Generation EGFR Inhibitor
Kim, Youngwook
Ko, Jeonghun
Cui, Zhengyun
Abolhoda, Amir
Lee, Jeeyun
Ahn, Jinseok
Ou, Sai-Hong
Ahn, Myung-Ju
Park, Keunchil
JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (12) : S421 - S421
[44] Combined plasma and tissue genotyping of EGFR T790M benefits NSCLC patients: a real-world clinical example
Wei, Bing
Zhao, Chengzhi
Li, Jun
Zhao, Jiuzhou
Ren, Pengfei
Yang, Ke
Yan, Chi
Sun, Rui
Ma, Jie
Guo, Yongjun
MOLECULAR ONCOLOGY, 2019, 13 (05) : 1226 - 1234
[45] KRAS and EGFR Amplifications Mediate Resistance to Rociletinib and Osimertinib in Acquired Afatinib-Resistant NSCLC Harboring Exon 19 Deletion/T790M in EGFR
Nakatani, Kaori
Yamaoka, Toshimitsu
Ohba, Motoi
Fujita, Ken-Ichi
Arata, Satoru
Kusumoto, Sojiro
Taki-Takemoto, Iori
Kamei, Daisuke
Iwai, Shinichi
Tsurutani, Junji
Ohmori, Tohru
MOLECULAR CANCER THERAPEUTICS, 2019, 18 (01) : 112 - 126
[46] Successful treatment with osimertinib for leptomeningeal carcinomatosis from NSCLC with the EGFR T790M mutation
Yoshimura, Naruo
Takahashi, Hidenori
Kurosawa, Emiko
Tanaka, Akiko
Ebina, Masahito
Ohrui, Takashi
ANNALS OF ONCOLOGY, 2019, 30 : 139 - 139
[47] KRAS amplification mediates resistance to osimertinib in acquired afatinib-resistant NSCLC harboring exon 19 deletion/T790M in EGFR
Yamaoka, Toshimitsu
Motoi, Ohba
Kishino, Yasunari
Kusumoto, Sojiro
Tsurutani, Junji
Ohmori, Tohru
CANCER RESEARCH, 2019, 79 (13)
[48] Acquired resistance of pulmonary adenocarcinoma to initially successful targeted therapy due to EGFR mutation T790M
Jancarikova, D.
Pesek, M.
Benesova, L.
Topolcan, O.
Holubec, L., Jr.
Minarik, M.
ANTICANCER RESEARCH, 2007, 27 (4A) : 1879 - 1882
[49] Exploratory study on detecting EGFR mutation including T790M with blood samples from patients with NSCLC
Kawamura, Takahisa
Murakami, Haruyasu
Kenmotsu, Hirotsugu
CANCER SCIENCE, 2018, 109 : 1100 - 1100
[50] ROS1 Translocation as a Bystander Mutation in T790M EGFR Mutated NSCLC
Stratmann, Jan
Kriegsmann, Joerg
Sulzbach, Bernd
Thoeming, Bernd
Serve, Hubert
Sebastian, Martin
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1260 - S1260

← 1 2 3 4 5 →